Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 1,206.00
+6.50 (0.54%)
Nov 12, 2026, 3:29 PM IST
Zydus Lifesciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Zydus Lifesciences stock has a consensus rating of "Hold" and an average price target of ₹1,238. The average 1-year stock price forecast is 2.69% higher than the current stock price, while the lowest is ₹800.00 (-33.67%) and the highest is ₹1,457 (+20.85%).
Price Target: ₹1,238 (+2.69%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Zydus Lifesciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 8 | 8 | 8 |
| Buy | 9 | 9 | 7 | 7 | 7 | 7 |
| Hold | 10 | 10 | 8 | 9 | 8 | 8 |
| Sell | 2 | 2 | 4 | 3 | 3 | 3 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 30 | 31 | 30 | 30 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains ₹1,250 | Hold | Maintains | ₹1,250 | +3.65% | Nov 5, 2026 |
| Citi | Citi | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 5, 2026 |
Financial Forecast
Revenue This Year
322.28B
from 271.48B
Increased by 18.71%
Revenue Next Year
357.91B
from 322.28B
Increased by 11.06%
EPS This Year
39.52
from 54.00
Decreased by -26.81%
EPS Next Year
49.65
from 39.52
Increased by 25.64%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.